The conventional process for designing a clinical formulation of a small molecule drug typically begins with experimental polymorph screening and scale-up studies. This process aims to identify and characterize the different polymorphs of the active pharmaceutical ingredient (API) and to select the most suitable one for development. However, this process can be time consuming and may miss some important low energy polymorphs due to the inability to exhaust all crystallization conditions. As such, inexhaustive polymorph screening poses serious challenges for drug development and manufacturing.